Crowdonomics
All companies
Immergo Labs logo

Immergo Labs

Operating

Immergo Labs, Inc.

Healthcare · Santa Cruz, CA · Founded 2022

Redefining telehealth for physical therapy

Post-money valuation ⓘ
$19.7M
As of Dec 2022 · from Reg CF Offering (2022) · pre-money + amount raised, not a traded price
Total raised
$154,877
Crowd $154K · Private $770 · 2 rounds since 2022
Latest share price
$2.24
Reg CF · Common Stock · Sep 2022 offering price

Financials

FY2020–FY2024 · from SEC filings · hover any figure for its source
$0
2020
$0
$13K
2021
$0
−$84K
2022
$43K
−$97K
2023
$301K
−$59K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020 reviewed*
FY2021 reviewed*
FY2022 unaudited
FY2023 unaudited
FY2024
Income statement
Revenue
$0
$0
$0
$42,832
$300,812
Cost of goods sold
$0
$0
$8,253
$12,397
$238,295
Gross margin
—
—
—
71%
21%
Net income
$0
$13,456
-$83,533
-$97,195
-$59,493
Taxes paid
$0
$0
$1,600
$848
$800
Balance sheet
Cash
$0
$14,981
$94,653
$49,557
$30,699
Accounts receivable
$0
$0
$0
$0
$0
Total assets
$0
$14,981
$97,599
$49,557
$54,076
Short-term debt
$0
$0
$900
$12,099
$1,431
Long-term debt
$0
$1,294
$0
$20,000
$147,000
Total liabilities
$0
$1,294
$900
$32,099
$148,431
Other
Headcount
—
3
3
3
6

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$19.5M
pre-money
Reg CF · Common · Sep 2022

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

log scale
$2.24$0.015$0.0001
Mar 2022Sep 2022
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Cap table

Principal holders% as the filing states it, Sep 22, 2022

  • Aviv Elor50.0%of company
  • Mircea Teodorescu25.0%of company
  • Sri Kurniawan25.0%of company

Sold to the crowd

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Raised $154.1K / $1.1MInvestors 113Post-money $19.7M

Team

7 people
Ash RobbinsFounder
Chief Technology Officer, co-founder, machine learning lead & director

Ash Robbins leads artificial intelligence design, manages cloud architecture integration, and ensures development meets technical validation. He has extensive development experience in machine learning and cloud computing from bio-inspired robotics to rehabilitation movement and modeling. He previously has worked on robots with adjustable dynamic properties and developing neural data from complex cloud architectures. His focus is on generalization in algorithmic design, using data driven approaches to quantify uncertainty. Robbins is currently a PhD Candidate at UCSC and upon graduation in 2023 will pursue commercialization of Immergo's core technology full time. Robbins works closely with Elor to lead technical operations.

Aviv ElorFounder
Chief Research and Experience Officer, co-founder, UX Lead, & director

Aviv Elor is the chief research and experience officer at Immergo Labs, where he leads virtual reality development, user experience research, and product validation. He is an award-winning researcher with expertise in the design and validation of virtual environments for physical rehabilitation. Dr. Elor has previously worked in designing immersive experiences from healthcare to entertainment between mixed academic-industry channels with organizations such as the National Institutes of Health, Meta (Facebook/Oculus) Reality Labs, Google Daydream, Warner Bros Entertainment, and Walt Disney Imagineering. After rupturing his own elbow in a national judo match and undergoing reconstructive surgery, he became a passionate developer for assistive technologies towards more accessible, affordable, and accurate physical therapy tools.

Michael Ora PowellFounder
CEO, co-founder, biomechanics lead, & director

Michael is the Chief Executive Officer of Immergo Labs where he leads the business and biomechanics aspects of the company. Dr. Powell has received Bachelors' degress in physics kinesiology, a Master's degree in exercise science with a focus in biomechanics, and a PhD in computer engineering where is research focused on developing machine learning algorithms to estimate joint mechanics during virtual reality rehabilitation. Michael grew up playing sports, sparking his interest in physical performance and recovery which steered his research for the last several years. Now he hopes to take his experience and develop tools to help others in their recovery process.

Greg Gewickey
Strategic Business Advisor

Greg Gewickey as a Technology Executive and Strategy Advisor at Gewickey Consulting, he engages with clients to develop robust corporate strategies. Greg has more than 35 years of industry experience in strategic planning, technology innovation, product management, and startup acceleration from organizations such as Amazon Web Services, IBM, Philips Electronics, InterActual, Walt Disney, and Warner Bros.

Mircea Teodorescu
Engineering Advisor

Mircea Teodorescu is a Professor in the Department of Electrical and Computer Engineering at University of California, Santa Cruz. He is a systems engineer and biomechanical specialist with research focus on the development of emerging technologies to improve quality of life from bioengineering, bioelectronics, and robotics.

Sean Wells
Physical Therapy Advisor

Sean Wells, DPT, OCS, ATC, CSCS, NSCA-CPT, CNPT, CERTDN is an expert concierge PT and a member of the APTA, NATA, and NSCA. Dr. Wells owns 4 concierge PT practices, has over 10 years of private PT business experience and has led research trials in applying emerging technology to concierge patients and garnering data with products including Nike Strobe glasses, Alter G, and vibration platforms. Through his concierge PT expertise and the hands-on application of the tech for research, Dr. Wells informs the discovery of new needs, tools, or settings.

Sri Kurniawan
User Experience and Accessibility Advisor

Sri Kurniawan is the Chair and Professor of Computational Media at UC Santa Cruz, where she leads research and development of assistive technology to help people with special needs maintain a high quality of life. Kurniawan has more than 20 years of experience in human-centered design, research collaborations with companies such as Microsoft, IBM Accessibility Lab, and others. Additionally, Kurniawan specializes in VR rehabilitation and has been involved with five NSF Basic Research Grant Projects over the past decade in designing and evaluating assistive technologies.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Not requiredFewer than 300 holders of record

Filed 3 of 4 annual reports (FY2022–FY2025)

113 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-ARMay 1, 20250001665160-25-000923
    EDGAR
  • Form C-ARMar 22, 20240001665160-24-000245
    EDGAR
  • Form C-ARMay 1, 20230001665160-23-001086
    EDGAR
  • Form C-UJan 24, 20230001665160-23-000128
    EDGAR
  • Form C/ADec 15, 20220001665160-22-003078
    EDGAR
  • Form C/ASep 22, 20220001665160-22-002466
    EDGAR
  • Form CSep 22, 20220001665160-22-002462
    EDGAR
Source: ManualCIK 0001947217DEShare price $2.24

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.